ASCO 2026 Brings New Frontline Strategies for Lung Cancer’s Hardest-to-Treat Subtypes: Five Trials to Watch

Lung cancer remains the leading cause of cancer death globally, accounting for more deaths annually than breast, colorectal, and prostate cancers combined. But the disease has changed. Over the past decade, oncologists have learned to look inside the tumor — not just at the tissue — and ask what genetic error is driving it. The answers have generated a new class of precision medicines, each matched to a specific molecular target, each displacing chemotherapy one subtype at a time.

ASCO 2026, running May 29–June 2 in Chicago, puts five lung cancer trials at the center of that story. Together, they span the full arc of the disease: a first-in-class antibody-drug conjugate combination rewriting the frontline immunotherapy standard, first-line treatment of the most stubbornly resistant EGFR subtype, management of immunotherapy-resistant mutations, and long-term questions about whether the newest targeted agents can eliminate disease before it metastasizes. Looming over all of it — and referenced throughout the thoracic oncology community heading into the meeting — is the seven-year update of the CROWN trial, the longest follow-up ever reported for any ALK inhibitor in a phase 3 setting. That data, already released ahead of the meeting, has begun to reframe stage IV lung cancer as something closer to a chronic, manageable condition than a terminal one, and it sets the benchmark against which everything else presented this week will be measured.

Sac-TMT Combination Marks First Successful Phase 3 ADC–Checkpoint Inhibitor Trial in Frontline NSCLC

Abstract 8506 | Trial: NCT06448312

For patients with advanced NSCLC whose tumors express PD-L1 — a protein that signals responsiveness to immunotherapy — pembrolizumab monotherapy has been the first-line standard since 2016, particularly for those with high PD-L1 expression. It works well for some patients, but a substantial proportion progress within months, and improving on single-agent pembrolizumab in this population has proven difficult. Chemotherapy combinations help but bring toxicity. A cleaner, more potent pairing has been the field’s outstanding question.

OptiTROP-Lung05 answers it for the first time with an antibody-drug conjugate. Sacituzumab tirumotecan (sac-TMT) is a TROP2-directed ADC — a precision-guided payload that binds to a protein overexpressed on many lung cancer cells and delivers a cytotoxic agent directly inside the tumor. The phase 3 trial randomized 413 patients with PD-L1–positive, locally advanced or metastatic NSCLC without EGFR or ALK alterations to sac-TMT plus pembrolizumab or pembrolizumab alone. At a prespecified interim analysis, the combination produced a 65% reduction in the risk of progression or death, with a positive overall survival trend also observed. This is the first phase 3 trial of an ADC combined with an immune checkpoint inhibitor to meet its primary endpoint in the first-line NSCLC setting.

Why it matters: ADC-immunotherapy combinations have reshaped treatment in breast and bladder cancer; OptiTROP-Lung05 marks their arrival in frontline lung cancer. A positive result in PD-L1–positive NSCLC — one of the most broadly treated populations in all of oncology — would introduce a fundamentally new treatment approach with implications for how pembrolizumab monotherapy is used and how subsequent ADC combinations in lung cancer are designed.

WU-KONG28 Tests Whether EGFR Exon 20 NSCLC Can Finally Move Beyond Chemotherapy

Abstract LBA8500 | Trial: NCT05668988

EGFR — the epidermal growth factor receptor — is the most common driver mutation in non-small cell lung cancer (NSCLC), present in roughly 15% of cases in Western populations and at higher rates in Asian populations. But not all EGFR mutations respond equally to targeted therapy. The “classic” EGFR mutations in exon 19 and exon 21 are highly responsive to existing tyrosine kinase inhibitors, while exon 20 insertion mutations have historically been much harder to target because of structural changes in the receptor that limit drug binding. Patients with EGFR exon 20 insertion NSCLC — which accounts for roughly 4–12% of EGFR-mutant lung cancers — have therefore largely relied on platinum-based chemotherapy in the frontline setting.

WU-KONG28 evaluates whether that paradigm can finally change. The multinational phase 3 randomized study compares sunvozertinib (Zegfrovy), an oral inhibitor specifically engineered to target EGFR exon 20 insertion mutations, against platinum-based chemotherapy in treatment-naïve patients with locally advanced or metastatic NSCLC harboring exon20ins alterations. Ahead of the meeting, topline data released by the company reported statistically significant improvements in progression-free survival, response rate, disease control rate, and duration of response with sunvozertinib compared with chemotherapy. The FDA granted accelerated approval to sunvozertinib in the second-line setting in 2025, and WU-KONG28 now evaluates whether the drug could move into the frontline standard-of-care setting.

Why it matters: A positive phase 3 result could reshape frontline treatment for EGFR exon 20 insertion NSCLC — one of the historically hardest-to-target subsets of EGFR-driven lung cancer — and further extend the shift toward precision-targeted therapy across increasingly rare molecular subtypes.

HARMONi-6: Bispecific Checkpoint Therapy Emerges as a Potential New Approach in Squamous NSCLC

Abstract LBA4 | Trial: NCT05840016

Squamous non-small cell lung cancer (NSCLC) accounts for roughly one-quarter of all NSCLC cases and has historically seen fewer advances in precision oncology than non-squamous disease, largely because most patients lack targetable driver mutations. Frontline treatment currently combines immune checkpoint inhibition with platinum-based chemotherapy, but outcomes remain limited for many patients, particularly outside highly selected biomarker-defined groups.

Ivonescimab is a bispecific antibody engineered to simultaneously target PD-1 and VEGF — combining immune checkpoint blockade with anti-angiogenic activity in a single molecule. The phase 3 HARMONi-6 trial compares ivonescimab plus chemotherapy against tislelizumab plus chemotherapy in previously untreated advanced squamous NSCLC. Data previously presented at ESMO 2025 reported that the ivonescimab combination extended progression-free survival by 4.2 months and reduced the risk of progression by 40% compared with the control arm. Benefit was observed across PD-L1 subgroups, suggesting activity beyond the biomarker populations typically used to guide immunotherapy selection. The ASCO 2026 presentation is expected to provide the trial’s overall survival results.

Why it matters: If the survival benefit confirms, HARMONi-6 could position ivonescimab as a potential new frontline treatment option for squamous NSCLC and further strengthen interest in dual-target immunotherapy strategies that combine checkpoint inhibition with anti-angiogenic mechanisms in a single therapy.

Targeted Therapy Advances Into the Post-Surgical Setting for RET-Positive NSCLC

Abstract LBA3 | Trial: NCT04819100

The story of targeted therapy in lung cancer has largely been a metastatic disease story — drugs developed for stage IV patients before gradually moving earlier in treatment. LIBRETTO-432 represents the next frontier: bringing a targeted inhibitor into the adjuvant setting, meaning after surgery, to reduce the risk of the cancer returning.

RET fusions — genomic rearrangements that create continuously active growth signaling — occur in approximately 1–2% of NSCLC cases, representing an estimated 20,000–30,000 patients globally each year. LIBRETTO-432 evaluates whether patients with stage IB–IIIA RET fusion-positive NSCLC who have undergone surgical resection benefit from three years of adjuvant selpercatinib (Retevmo), a highly selective RET inhibitor, compared with placebo. The primary endpoint is event-free survival — the length of time before recurrence, development of a new primary lung cancer, or death.

Why it matters: Reducing recurrence risk after surgery remains one of the most emotionally and clinically significant challenges in lung cancer care. A targeted adjuvant strategy that meaningfully lowers that risk — similar to how adjuvant osimertinib reshaped EGFR-mutant disease — would extend precision medicine into the curative-intent setting for RET-positive NSCLC for the first time.

Dual Checkpoint Immunotherapy Targets One of Lung Cancer’s Most Immunotherapy-Resistant Subsets

Abstract 8515 | Trial: NCT06008093

For all the advances in precision oncology, a significant subset of lung cancer patients continues to derive limited benefit from immunotherapy — not because their tumors are invisible to treatment, but because certain mutations actively suppress immune response inside the tumor microenvironment. STK11 and KEAP1 mutations, found in approximately 20% and 15% of non-squamous NSCLC patients respectively, have been associated with immunotherapy resistance and poor clinical outcomes, particularly when co-occurring with KRAS mutations.

TRITON takes the biomarker-driven approach one step further. Rather than relying on a single immune checkpoint inhibitor, the study evaluates dual checkpoint blockade using Durvalumab and Tremelimumab alongside chemotherapy. Each therapy targets a different immune suppressive pathway: durvalumab blocks PD-L1 signaling, while tremelimumab inhibits CTLA-4-mediated immune suppression. The underlying hypothesis is that tumors harboring STK11, KEAP1, and KRAS mutations may require a more intensive immune-based strategy to overcome their highly immunosuppressive biology.

The phase 3b TRITON study compares durvalumab plus tremelimumab and chemotherapy against standard Pembrolizumab plus chemotherapy in first-line metastatic non-squamous NSCLC with STK11, KEAP1, and/or KRAS mutations. The primary endpoint is overall survival.

Why it matters: TRITON focuses on one of the most treatment-resistant molecular subsets in lung cancer — patients who have historically experienced poorer outcomes even in the immunotherapy era. A positive result could establish one of the first biomarker-selected immunotherapy strategies specifically designed around mechanisms of immune resistance, while also redefining dual CTLA-4/PD-L1 blockade as a precision immuno-oncology approach rather than a broad, non-selective intensification strategy.

The Bigger Picture in Lung Cancer at ASCO 2026

Three themes run through this year’s thoracic oncology slate. First, precision medicine is moving earlier in the treatment course: selpercatinib in the adjuvant setting and sunvozertinib in the frontline setting both reflect targeted therapies being deployed before patients exhaust conventional treatment options. Second, new therapeutic strategies are beginning to reshape lung cancer treatment paradigms: OptiTROP-Lung05 represents one of the first successful phase 3 demonstrations of an ADC-immunotherapy combination in frontline NSCLC, a setting where pembrolizumab-based approaches have dominated for nearly a decade. Third, immunotherapy-resistant patient populations are receiving direct attention through biomarker-selected trial designs such as TRITON, rather than being treated as poorly responsive subgroups within broader all-comer studies.

Author

Bernice Lottering